ISRCTN36658311已完成不适用
A multicentre study of the safety and efficacy of N-acetylcysteine in the treatment of acute liver failure in paediatric patients not caused by acetaminophe
King's College Hospital NHS Foundation Trust (UK)0 个研究点目标入组 28 人开始时间: 2010年5月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Enrolment in PALF registry:
- •1. Evidence of acute liver injury
- •2. International normalised ratio (INR) greater than or equal to 1.5 or prothrombin time (PT) greater than or equal to 15 with encephalopathy, or INR greater than or equal to 2.0 or PT greater than or equal to 20 with or without encephalopathy
- •3. Aged less than 18 years, either sex
- •4. Informed consent, obtained from the patient or parent
排除标准
- •1. Acute paracetomol toxicity
- •2. Patient on N-acetylcysteine or received N-acetylcysteine during the course of this illness
- •3. Pregnancy
- •4. Known malignancy
- •5. Patient is on a liver support device
- •7. Signs of cerebral herniation
- •8. Intractable hypotension
研究者
相似试验
已完成
不适用
A multi-center study of the safety and efficacy of the percutaneous transvenous mitral annuloplasty system to reduce mitral valve regurgitation in patients with heart failure.mitral regurgitationmitral valve leakage10046973NL-OMON33252Viacor Inc.14
已完成
不适用
A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in patients with hypophosphatasia (HPP)hypophosphatasiaJPRN-UMIN000014816HPP study group20
进行中（未招募）
不适用
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)EUCTR2006-006522-25-BECSL Behring AG28
进行中（未招募）
不适用
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencyEUCTR2006-006522-25-DECSL Behring AG28
进行中（未招募）
1 期
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencyEUCTR2006-006522-25-GRCSL Behring AG18